[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Hall8Jack Jack HallJack Hall posts on X about $srpt, $arwr, $dyn, $nvs the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence stocks XXXX% cryptocurrencies XXXX%
Social topic influence $srpt #19, $arwr #17, $dyn #12, $nvs #10, $rna #13, $mdgl 3.13%, the new 3.13%, $vrtx 3.13%, $trda 3.13%, vrtx XXXX%
Top accounts mentioned or mentioned by @artsstocks @richtrades100 @biotechanalysst @bikerieder @rnaianalyst @commonsenseplay @biopharmacaster @jamesmclaw70633 @aistocksavvy @yachmod @doepkemichel @biotecisfuture @timcarmichael3 @theprofessor85 @sangamotx @titteridiot1 @singlemalt18 @morganstanley @lsinnv @avidresearch
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Arrowhead Research Corporation (ARWR) Dyne Therapeutics, Inc. Common Stock (DYN) Novartis AG (NVS) Avidity Biosciences, Inc. Common Stock (RNA) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Vertex Protocol (VRTX)
Top posts by engagements in the last XX hours
"@doepke_michel So besides $mdgl - also add $arwr to this potential BO list Or is arwr simply the new spec obesity ticker 🤷🏽"
X Link 2025-11-26T15:25Z 1639 followers, XXX engagements
"@richtrades100 @biopharmacaster $dyn safety for x51 looks worse than $srpt . Will be key consideration"
X Link 2025-12-08T11:53Z 1639 followers, XXX engagements
"@BiotechAnalysst Really need a detailed safety breakdown also"
X Link 2025-12-08T18:52Z 1639 followers, XXX engagements
"@RNAiAnalyst @JamesMclaw70633 $vrtx $trda also IV in DM1"
X Link 2025-11-15T19:00Z 1640 followers, XXX engagements
"@richtrades100 @biopharmacaster Ppmo-51 had Mg problems. Not Eteplirsen. I stand by my statement. dyn51 had clinical hold. Not good for chronic tx. $dyn $srpt"
X Link 2025-12-08T11:58Z 1640 followers, XXX engagements
"@avidresearch @JacobPlieth $srpt v $capr - apples to oranges but :"
X Link 2025-12-03T17:50Z 1640 followers, XXX engagements
"$arwr +12% today presented at PS Conference; worth a listen (also $srpt $nvs ). Was an RNA panel discussion afterward:"
X Link 2025-12-03T21:00Z 1640 followers, 1056 engagements
"$srpt / Endeavor cohort 8/sirolimus related (also $rgnx $sldb etc #GeneTherapy ) :"
X Link 2025-12-04T21:16Z 1640 followers, XXX engagements
"@BikeRieder Little bit surprised $nvs went with $arwr deal for aro-snca/PD instead of aro-mapt/AD. Do you think aro-mapt too expensive asset or nvs saw higher prob of success for aro-snca $Srpt also passed on aro-mapt (in favor of Ataxia1-3; HD CNS assets) so same type of question"
X Link 2025-12-07T13:53Z 1640 followers, XXX engagements
"$dyn safety not as good as $srpt Etep. Srpt also had ppmo51 which was discontinued due to safety and dyne-251 is very close analog. I would scrutinize ongoing chronic safety data very closely. This safety is very mixed and read note 5- ie why did they choose not to report on safety events after 8/19/25"
X Link 2025-12-08T16:10Z 1640 followers, 1219 engagements
"@BiotechAnalysst No new persistent thrombocytopenia for more than X months tough for a chronic tx. $dyn $rna $srpt"
X Link 2025-12-08T19:54Z 1640 followers, XXX engagements
"@bioinvestor24 Is this correct summary: $dyn dyne-251 produces 7fold increase of D over baseline $rna del-zota produces 4-5fold increase over baseline And according to this $srpt Etep produces 7fold increase over baseline"
X Link 2025-12-09T00:14Z 1640 followers, XXX engagements
"$arwr Related to $srpt subQ CNS Ataxias/Huntingtons Disease programs:"
X Link 2025-12-10T14:59Z 1640 followers, 1452 engagements
"@BikeRieder Do you know if this will be owned by $arwr or this is one of the $srpt agreed to programs"
X Link 2025-12-10T16:11Z 1640 followers, XXX engagements
"@FirstSquawk lol Nvda knew full well what was going on"
X Link 2025-12-10T18:17Z 1640 followers, XX engagements